AI Target Identification in Drug Discovery

A drug target is a biological molecule or process that a therapy is intended to affect. Identifying a useful target requires evidence that it is involved in disease and that modulating it could produce a beneficial effect. AI and data platforms can combine genetics, gene expression, protein interactions, model-organism experiments, clinical studies, and literature. Open Targets describes its platform as integrating evidence to support systematic target identification and prioritization; a score organizes evidence but does not establish causality or therapeutic value. Evidence types answer different questions. A genetic association may indicate a relationship with disease risk, while expression data may show a difference in a tissue. Neither alone proves that a drug acting on the target will help patients. A target may be difficult to reach with a drug, have harmful effects in other tissues, or matter only in a specific disease stage. Researchers consider direction of effect, biological mechanism, safety, and experimental tractability. After computational ranking, teams test target perturbation in relevant cells or models, reproduce findings with independent methods, and check that effects are not artifacts. Human genetics can strengthen a hypothesis, but patient biology and treatment safety still need study. Keep provenance for each evidence item and distinguish direct experimental findings from indirect associations. AI can help prioritize experiments; it cannot replace target validation or demonstrate a medicine’s clinical benefit.